CNTN
Tharimmune, Inc.
NASDAQ · USHealthcareBiotechnology
$2.05-10.87%
Price as of Jul 20, 2026
CNTN financials
Tharimmune, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $20.1M | $12.4M | $9.5M | $6.9M |
| Operating income | -$20.1M | -$12.4M | -$9.5M | -$6.9M |
| Net income | -$35.9M | -$12.2M | -$9.3M | -$8.5M |
| EBITDA | -$42.1M | -$12.2M | -$9.1M | -$6.7M |
| Basic EPS | $-1.12 | $-9.41 | $-107.08 | $-280.77 |
| Diluted EPS | $-1.12 | $-9.41 | $-107.08 | $-280.77 |
| Balance sheet | ||||
| Cash & equivalents | $17.0M | $3.6M | $10.9M | $6.5M |
| Total assets | $519.1M | $3.7M | $10.9M | $6.7M |
| Total liabilities | $121.2M | $2.4M | $1.8M | $1.1M |
| Stockholders’ equity | $397.9M | $1.3M | $9.1M | $5.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$17.0M | -$3.6M | -$10.9M | -$6.5M |
| Cash flow | ||||
| Operating cash flow | -$16.1M | -$10.9M | -$7.3M | -$6.6M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$16.1M | -$10.9M | -$7.3M | -$6.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | -$70.0K |